WARRINGTON, Pa., Dec. 7, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), today announced that new Aerosurf® data in a study employing the well-established preterm lamb model of respiratory distress syndrome (RDS) were presented at the 2010 Annual Hot Topics in Neonatology congress in Washington, DC. Key observations from this preclinical study, conducted at the Temple University School of Medicine, suggest that Aerosurf may improve lung function and reduce the inflammatory response associated with lung injury and the development of chronic lung disease in a dose-dependent fashion and at reduced dose exposures compared with previous studies in this non-clinical model. Aerosurf is an aerosolized form of Discovery Labs’ proprietary KL4 surfactant.
